Differential role of <i>CREBBP</i> missense and truncating mutations in germinal center development and lymphomagenesis

C Chuanjiang Yu (1Institute for Cancer Genetics, Columbia University, New York, NY) M Mara Holloman (1Institute for Cancer Genetics, Columbia University, New York, NY) A Andrew Kim Y Yunchao Chang (1Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN) S Stefanie N. Meyer (1Institute for Cancer Genetics, Columbia University, New York, NY) A Antony B. Holmes B Bowen Cai T Tongwei Mo (1Institute for Cancer Genetics, Columbia University, New York, NY) K Katia Basso (1Institute for Cancer Genetics, Columbia University, New York, NY) K Kostiantyn Dreval (4Centre for Lymphoid Cancer, BC Cancer Research Institute, Vancouver, BC, Canada) R Ryan D. Morin (4Centre for Lymphoid Cancer, BC Cancer Research Institute, Vancouver, BC, Canada) G Govind Bhagat C Charles G. Mullighan R Riccardo Dalla-Favera (1Institute for Cancer Genetics, Columbia University, New York, NY) L Laura Pasqualucci (1Institute for Cancer Genetics, Columbia University, New York, NY)

Abstract

Abstract Truncating and missense mutations of the CREBBP gene are highly prevalent in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), the most common lymphoid malignancies. These mutations are acquired early during tumor evolution by a common precursor cell (CPC) and lead to either complete protein loss or single amino acid substitutions in the lysine acetyltransferase (KAT) domain. As a result, CREBBP is impaired in its ability to acetylate enhancer histones and nonhistone proteins implicated in the germinal center (GC) reaction, the structure from which these tumors originate. However, whether truncating and KAT domain missense mutations are functionally equivalent in instructing the CPC remains unexplored. Using a conditional GC-specific knockin mouse model for the highly frequent CREBBP-R1446H amino acid change (CrebbpRH), we show that, compared with complete Crebbp loss, missense mutants impose distinct quantitative and qualitative effects on the GC response. CrebbpRH controls unique transcriptional programs leading to the preneoplastic expansion of GCs with abnormal architecture, increased percentage of T follicular helper cells, and a skewed immune response toward memory B-cell differentiation. The expression of CrebbpRH, but not Crebbp loss, was by itself sufficient to initiate malignant transformation, indicating a stronger tumor-promoting activity. Notably, lymphoma cells with CREBBPRH and CREBBP loss showed distinct sensitivity to CREBBP/p300 small-molecule inhibitors. Together with the differential distribution of missense and truncating mutations in FL and DLBCL, these findings have implications for the pathogenesis and therapeutic targeting of these cancers.

Article Details

Journal Blood
Volume / Issue Vol. 147, Issue 23
Published June 04, 2026
Pages 2713-2727
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (15)

C

Chuanjiang Yu

1Institute for Cancer Genetics, Columbia University, New York, NY

M

Mara Holloman

1Institute for Cancer Genetics, Columbia University, New York, NY

A

Andrew Kim

Y

Yunchao Chang

1Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN

S

Stefanie N. Meyer

1Institute for Cancer Genetics, Columbia University, New York, NY

A

Antony B. Holmes

B

Bowen Cai

T

Tongwei Mo

1Institute for Cancer Genetics, Columbia University, New York, NY

K

Katia Basso

1Institute for Cancer Genetics, Columbia University, New York, NY

K

Kostiantyn Dreval

4Centre for Lymphoid Cancer, BC Cancer Research Institute, Vancouver, BC, Canada

R

Ryan D. Morin

4Centre for Lymphoid Cancer, BC Cancer Research Institute, Vancouver, BC, Canada

G

Govind Bhagat

C

Charles G. Mullighan

R

Riccardo Dalla-Favera

1Institute for Cancer Genetics, Columbia University, New York, NY

L

Laura Pasqualucci

1Institute for Cancer Genetics, Columbia University, New York, NY